Loading...
Market
Story
Summit Therapeutics' Stock Soars 225% After PD-1 Drug Ivonescimab Outperforms Keytruda in PFS NSCLC Trial in China
May 30, 2024, 07:10 PM
Summit Therapeutics' stock ($SMMT) surged by 225% following the announcement that its drug Ivonescimab, a PD-1 inhibitor, achieved a clinically meaningful benefit over Merck's Keytruda (Pembrolizumab) in a Phase III trial. The trial, named HARMONi-2, met its primary endpoint of progression-free survival (PFS) for patients with advanced non-small cell lung cancer (NSCLC) with PD-L1 expression. This unprecedented result caused Merck's ($MRK) shares to drop by 1.20% before rebounding slightly. BioNTech ($BNTX) shares also rose by 10% on the news. Summit's stock experienced multiple trading halts, with the second halt occurring at a 137% increase and close to $10 per share. The market cap of Summit Therapeutics is now estimated at $5 billion. The trial data was collected in China.
View original story
Similar markets
Below $50 • 33%
Between $50 and $100 • 33%
Above $100 • 33%
Increase by 50% or more • 25%
Increase by 1-49% • 25%
No change or decrease by 1-49% • 25%
Decrease by 50% or more • 25%
Additional Phase 3 trials • 33%
FDA Approval without additional trials • 33%
FDA Rejection • 33%
Less than 500 million USD • 25%
500 million - 1 billion USD • 25%
1 billion - 2 billion USD • 25%
More than 2 billion USD • 25%
FDA approval application • 25%
Partnership with another company • 25%
Further clinical trials • 25%
No significant action • 25%